To reach the next value inflection
LicenseRx asset brief
Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer
Probability of Success
27% · grade B · Medium data confidence
Model PoS 27% (grade B, medium data confidence). Strongest signals: IP position, Data maturity. Biggest drag: Competitive whitespace.
Data maturity (22%)
63
Preclinical; in vivo data, clinical reference.
IP position (16%)
88
Issued/granted patent on record.
Modality feasibility (14%)
82
Small molecule -- well-trodden regulatory and CMC path.
Indication pull (14%)
82
Oncology -- active buyer appetite.
Competitive whitespace (12%)
60
Crowded oncology field.
Translational evidence (12%)
70
Public evidence mentions: clinical, in vivo, potency.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →